Table 1. Donors' characteristics.
| Donors | Gender | Age (year) | DAS28 score | ESR (mm h−1) | ACPA (U ml−1) | RF (U ml−1) | Non steroid anti-inflammatory drugs | MTX (mg per week) | Anti-TNFα (mg per 2 weeks) | miRNA analysis type |
|---|---|---|---|---|---|---|---|---|---|---|
| Healthy controls | ||||||||||
| HC-2 | F | 44 | ND | ND | ND | ND | — | — | — | Array |
| HC-6b | F | 50 | ND | ND | ND | ND | — | — | — | Array |
| HC-1 | M | 45 | ND | ND | ND | ND | — | — | — | qRT–PCR validation |
| HC-3 | F | 52 | ND | ND | ND | ND | — | — | — | qRT–PCR validation |
| HC-5 | F | 53 | ND | ND | ND | ND | — | — | — | qRT–PCR validation |
| HC-7 | F | 48 | ND | ND | ND | ND | — | — | — | qRT–PCR validation |
| Newly diagnosed patients | ||||||||||
| RA new | ||||||||||
| RA-10 | M | 42 | 4.2 | 9 | 39 | 15 | Yes | — | — | Array |
| RA-27 | M | 50 | 2.9 | 15 | >340 | 650 | Yes | — | — | Array |
| RA-4 | M | 46 | 5.4 | 67 | 91 | 21 | Yes | — | — | qRT–PCR validation |
| RA-14 | F | 42 | 6.0 | 30 | 468 | 71 | Yes | — | — | qRT–PCR validation |
| RA-33 | F | 29 | 4.5 | 51 | >340 | 15 | Yes | — | — | qRT–PCR validation |
| RA-7 | M | 68 | 4.2 | 22 | >340 | 78 | Yes | — | — | qRT–PCR 2 |
| RA-12 | F | 43 | 3.8 | 11 | 43 | 196 | Yes | — | — | qRT–PCR 2 |
| RA-32 | F | 51 | 5.4 | 37 | 328 | 69 | Yes | — | — | qRT–PCR 2 |
| Treated patients | ||||||||||
| RA MTX | ||||||||||
| RA-15 | M | 45 | 1.3 | 3 | >340 | 53 | Yes | 25 | — | Array |
| RA-22 | F | 56 | 5.2 | 15 | >340 | 20 | Yes | 15 | — | Array |
| RA-1 | F | 60 | 5.3 | 20 | 0 | 0 | No | 15 | — | qRT–PCR validation |
| RA-9 | F | 80 | 4.0 | 33 | 0 | 0 | Yes | 20 | — | qRT–PCR validation |
| RA-21 | F | 54 | 2.8 | 38 | 107 | 71 | Yes | 15 | — | qRT–PCR validation |
| RA-26 | M | 67 | 3.4 | 11 | 0 | 16 | Yes | 15 | — | qRT–PCR validation |
| RA-13 | M | 50 | 3.9 | 6 | 0 | 0 | Yes | 25 | — | qRT–PCR 2 |
| RA-16 | F | 30 | 7.8 | 70 | 3 | 436 | Yes | 25 | — | qRT–PCR 2 |
| RA-18 | M | 50 | 3.7 | 3 | 1 | 13 | Yes | 25a | — | qRT–PCR 2 |
| RA-20 | F | 30 | 5.9 | 27 | 3 | 436 | Yes | 25a | — | qRT–PCR 2 |
| RA-23 | F | 48 | 3.1 | 13 | 34 | 31 | Yes | 25 | — | qRT–PCR 2 |
| RA MTX+anti-TNF-α | ||||||||||
| RA-8 | F | 41 | 2.7 | 5 | 15 | 224 | Yes | 15 | 40 | Array |
| RA-28 | F | 30 | 2.7 | 18 | 4 | 29 | Yes | 25 | 40 | Array |
| RA-2 | F | 62 | 2.7 | 12 | 42 | 33 | Yes | 15 | 40 | qRT–PCR validation |
| RA-29 | M | 59 | 2.7 | 6 | >340 | 590 | Yes | 10 | 40 | qRT–PCR validation |
| RA-30 | F | 55 | 2.8 | 24 | >340 | 593 | No | 20 | 40 | qRT–PCR validation |
| RA-3 | F | 61 | 2.6 | 18 | 1 | 54 | No | 15 | 40b | qRT–PCR 2 |
| RA-11 | M | 60 | 2.5 | 16 | >1000 | 331 | Yes | 12.5 | 40 | qRT–PCR 2 |
| RA-31 | F | 51 | 1.8 | 13 | >340 | 365 | No | — | 40 | qRT–PCR 2 |
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score; ESR, erythrocyte sedimentation rate; miRNA, microRNA; MTX, methotrexate; ND, not determined; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor.
a
Per 6 months.
b
Per month.